Anxiety is a significant mental health issue that substantially affects an individual’s quality of life. Feelings of uneasiness, irritability, and sleep disturbances characterize it. 4-Hydroxyphenyl acetic acid (4-HPAA) is identified in brain cells as a physiological byproduct of tyramine. This study hypothesizes that 4-HPAA may regulate anxiety due to its anxiolytic properties, acting as a modulator of the GABAergic system, which plays a crucial role in the pathophysiology of anxiety disorders. Our study aims to enhance the anxiolytic effects of 4-HPAA through chemical modification to improve its pharmacokinetic properties. Three derivatives, namely Isopropyl-4-hydroxy-[phenyl] acetate (IHPA), Isopropyl-4-hydroxy-[phenyl] acetate (MPAA), and 4-methoxyphenyl acetate (MPHA), have been synthesized from 4-HPAA. This assessment will use well-established animal models, specifically the Elevated Plus-Maze (EPM) and Zero Maze (EZM) tests, selected for their validity in replicating anxiety-like symptoms in animals. Chronic caffeine administration via drinking water (0.3 g/l for 14 days) was employed to induce an anxiety state for testing purposes. IHPA and MPAA demonstrated significant anxiolyticactivity when tested in the EPM and EZM experiments. Molecular docking simulations using AutoDock Vina indicated that 4-HPAA derivatives had docking scores ranging from ？5.8 to ？4.8 kcal/mol, compared to the standard anxiolytic medication Diazepam, which scored ？7.1 kcal/mol. These scores suggest a potential for 4-HPAA derivatives to interact effectively with the Gamma-aminobutyric acid (GABA_A) receptor. In conclusion, our in vivo and in silico analyses indicate a promising anxiolytic potential for 4-HPAA derivatives.
References
[1]
Teleanu, R.I., Niculescu, A., Roza, E., Vladâcenco, O., Grumezescu, A.M. and Teleanu, D.M. (2022) Neurotransmitters—Key Factors in Neurological and Neurodegenerative Disorders of the Central Nervous System. International Journal of Molecular Sciences, 23, Article No. 5954. https://doi.org/10.3390/ijms23115954
[2]
Klimes-Dougan, B., Begnel, E., Almy, B., Thai, M., Schreiner, M.W. and Cullen, K.R. (2019) Hypothalamic-Pituitary-Adrenal Axis Dysregulation in Depressed Adolescents with Non-Suicidal Self-Injury. Psychoneuroendocrinology, 102, 216-224. https://doi.org/10.1016/j.psyneuen.2018.11.004
[3]
Thibaut, F. (2022) Anxiety Disorders: A Review of Current Literature. Dialogues in Clinical Neuroscience, 19, 87-88.
[4]
Garakani, A., Murrough, J.W., Freire, R.C., Thom, R.P., Larkin, K., Buono, F.D., et al. (2020) Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options. Frontiers in Psychiatry, 11, Article 595584. https://doi.org/10.3389/fpsyt.2020.595584
[5]
Chaachouay, N. and Zidane, L. (2024) Plant-Derived Natural Products: A Source for Drug Discovery and Development. Drugs and Drug Candidates, 3, 184-207. https://doi.org/10.3390/ddc3010011
[6]
Yao, J., Ju, B., Li, X., Ma, M., Li, L. and Zhang, Y. (2022) Clinical Study of Comprehensive TCM Therapy in the Treatment of Damp and Hot Stasis Erectile Dysfunction. Medicine, 101, e30776. https://doi.org/10.1097/md.0000000000030776
[7]
Sarris, J., Marx, W., Ashton, M.M., Ng, C.H., Galvao-Coelho, N., Ayati, Z., et al. (2021) Plant-Based Medicines (Phytoceuticals) in the Treatment of Psychiatric Disorders: A Meta-Review of Meta-Analyses of Randomized Controlled Trials [Les médicaments à base de plantes (phytoceutiques) dans le traitement des troubles psychiatriques: Une méta-revue des méta-analyses d’essais randomisés contrôlés]. The Canadian Journal of Psychiatry, 66, 849-862. https://doi.org/10.1177/0706743720979917
[8]
Promden, W., Viriyabancha, W., Monthakantirat, O., Umehara, K., Noguchi, H. and De-Eknamkul, W. (2018) Correlation between the Potency of Flavonoids on Mushroom Tyrosinase Inhibitory Activity and Melanin Synthesis in Melanocytes. Molecules, 23, Article 1403. https://doi.org/10.3390/molecules23061403
[9]
Chen, W., Zhang, L., Zhao, L., Yan, F., Zhu, X., Lu, Q., et al. (2021) Metabolomic Profiles of A-Type Procyanidin Dimer and Trimer with Gut Microbiota in Vitro. Journal of Functional Foods, 85, Article ID: 104637. https://doi.org/10.1016/j.jff.2021.104637
[10]
Kalka, J. and Drzymała, J. (2023) Vicia Faba Plant Suitability Assessment for Genotoxicity, Cytotoxicity, and Mutagenicity Testing of Pharmaceutical-Containing Wastewater. Water, 15, Article No. 3044. https://doi.org/10.3390/w15173044
[11]
Costa, V.M., Grando, L.G.R., Milandri, E., Nardi, J., Teixeira, P., Mladěnka, P., et al. (2022) Natural Sympathomimetic Drugs: From Pharmacology to Toxicology. Biomolecules, 12, Article No. 1793. https://doi.org/10.3390/biom12121793
[12]
Serra, S., Castagna, A., Marzorati, S. and Valentino, M. (2022) Biotransformation of the Proteogenic Amino Acids Phenylalanine, Tyrosine and Tryptophan by Yarrowia Species: An Application to the Preparative Synthesis of Natural Phenylacetic Acid. Catalysts, 12, Article No. 1638. https://doi.org/10.3390/catal12121638
[13]
Alrumaihi, F., Almatroodi, S.A., Alharbi, H.O.A., Alwanian, W.M., Alharbi, F.A., Almatroudi, A., et al. (2024) Pharmacological Potential of Kaempferol, a Flavonoid in the Management of Pathogenesis via Modulation of Inflammation and Other Biological Activities. Molecules, 29, Article No. 2007. https://doi.org/10.3390/molecules29092007
[14]
Wu, X., Xu, J. and Wang, X. (2023) IDDF2023-ABS-0274 Bacteroides Vulgatus Affects Colitis and Depression-Like Behavior in Mice: Implications for the Gut-Brain Connection. BMJ Publishing Group, 72. https://doi.org/10.1136/gutjnl-2023-iddf.111
[15]
Vissiennon, C., Nieber, K., Kelber, O. and Butterweck, V. (2012) Route of Administration Determines the Anxiolytic Activity of the Flavonols Kaempferol, Quercetin and Myricetin—Are They Prodrugs? The Journal of Nutritional Biochemistry, 23, 733-740. https://doi.org/10.1016/j.jnutbio.2011.03.017
[16]
Moradi-Afrapoli, F., Oufir, M., Walter, F.R., Deli, M.A., Smiesko, M., Zabela, V., et al. (2016) Validation of UHPLC-MS/MS Methods for the Determination of Kaempferol and Its Metabolite 4-Hydroxyphenyl Acetic Acid, and Application to in Vitro Blood-Brain Barrier and Intestinal Drug Permeability Studies. Journal of Pharmaceutical and Biomedical Analysis, 128, 264-274. https://doi.org/10.1016/j.jpba.2016.05.039
[17]
Villanueva-García, D., Mota-Rojas, D., Miranda-Cortés, A., Mora-Medina, P., Hernández-Avalos, I., Casas-Alvarado, A., et al. (2020) Neurobehavioral and Neuroprotector Effects of Caffeine in Animal Models. Journal of Animal Behaviour and Biometeorology, 8, 298-307. https://doi.org/10.31893/jabb.20039
[18]
Liu, C., Wang, L., Zhang, C., Hu, Z., Tang, J., Xue, J., et al. (2024) Caffeine Intake and Anxiety: A Meta-analysis. Frontiers in Psychology, 15, Article 1270246. https://doi.org/10.3389/fpsyg.2024.1270246
[19]
Shoji, H. and Miyakawa, T. (2019) Age‐Related Behavioral Changes from Young to Old Age in Male Mice of a C57BL/6J Strain Maintained under a Genetic Stability Program. Neuropsychopharmacology Reports, 39, 100-118. https://doi.org/10.1002/npr2.12052
[20]
Gaspar, L., Bartman, S., Coppotelli, G. and Ross, J.M. (2023) Effect of Apparatus Characteristics on Anxiety-Like Behavior in Young Adult and Old Mice of Both Sexes Assessed by the Elevated Plus Maze Assay. Frontiers in Behavioral Neuroscience, 17, Article 1182661. https://doi.org/10.3389/fnbeh.2023.1182661
[21]
Gangopadhyay, A., Malakar, J., Ghosh, A., Deb, J., Dey, S., Datta, S., et al. (2012) The Central Nervous System Activity of Barleriaprionitis Linn. on the Locomotor Activity of Swiss Albino Mice Using Actophotometer. International Journal of Pharmaceutical and Biological Archive, 3, 403-405.
[22]
Pawar, R.P. and Rohane, S.H. (2021) Role of AutoDock Vina in PyRx Molecular Docking. Asian Journal of Research in Chemistry, 14, 132-134.
[23]
Zhang, C. and Du, W. (2024) The Mechanism of Celastrol in the Treatment of Metastatic Lung Adenocarcinoma Revealed by Network Pharmacology and Molecular Docking. Journal of Biosciences and Medicines, 12, 275-285. https://doi.org/10.4236/jbm.2024.126023
[24]
Carter, T. (2023) Understanding the Presentation and Treatment of Anxiety Disorders. Nursing Standard, 38, 73-77. https://doi.org/10.7748/ns.2023.e12166
[25]
Pandey, D.K., Devadoss, T., Modak, N. and Mahesh, R. (2016) Antidepressant & Anxiolytic Activities of N-[Pyridin-3-yl] Quinoxalin-2-Carboxamide: A Novel Serotonin Type 3 Receptor Antagonist in Behavioural Animal Models. Indian Journal of Medical Research, 144, 614-621.
[26]
Li, J., Wang, Q., Xia, G., Adilijiang, N., Li, Y., Hou, Z., et al. (2023) Recent Advances in Targeted Drug Delivery Strategy for Enhancing Oncotherapy. Pharmaceutics, 15, Article No. 2233. https://doi.org/10.3390/pharmaceutics15092233
[27]
Ekhator, C., Qureshi, M.Q., Zuberi, A.W., Hussain, M., Sangroula, N., Yerra, S., et al. (2023) Advances and Opportunities in Nanoparticle Drug Delivery for Central Nervous System Disorders: A Review of Current Advances. Cureus, 15, e44302. https://doi.org/10.7759/cureus.44302
[28]
Tucker, L.B. and McCabe, J.T. (2017) Behavior of Male and Female C57BL/6J Mice Is More Consistent with Repeated Trials in the Elevated Zero Maze than in the Elevated Plus Maze. Frontiers in Behavioral Neuroscience, 11, Article No. 13. https://doi.org/10.3389/fnbeh.2017.00013
[29]
Young, T.A., George, M., Gugssa, A., Southerland, W.M., Fang, Y. and Lee, C.M. (2024) Molecular Docking Studies on Streptomycin Antileishmanial Activity. Open Journal of Physical Chemistry, 14, 36-48. https://doi.org/10.4236/ojpc.2024.142003
